Literature DB >> 8622337

Graft-versus-myeloma effect in two cases.

L F Verdonck1, H M Lokhorst, A W Dekker, H K Nieuwenhuis, E J Petersen.   

Abstract

BACKGROUND: Allogeneic bone-marrow transplantation (BMT) is associated with the graft-versus-leukaemia effect because of the antileukaemic action of donor lymphocytes. We describe a graft-versus-myeloma effect after BMT in multiple myeloma.
METHODS: Two patients with recurrent multiple myeloma after allogeneic BMT (T cells partly depleted, 10(5) T cells infused per kg) received leucocyte infusions obtained by leukapheresis from their original marrow donors. The patients were a 48-year-old woman and a 49-year-old man.
FINDINGS: Both patients developed graft-versus-host disease and achieved complete remission of myeloma. Chimerism was complete in both patients in that all peripheral blood cells were of donor origin.
INTERPRETATION: We see our results as evidence for a graft-versus-myeloma effect. Using this form of adoptive immunotherapy, we could administer 1000-3000 times more T cells than with the earlier BMT.

Entities:  

Mesh:

Year:  1996        PMID: 8622337     DOI: 10.1016/s0140-6736(96)90871-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

1.  Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation.

Authors:  Melinda A Biernacki; Yu-tzu Tai; Guang Lan Zhang; Anselmo Alonso; Wandi Zhang; Rao Prabhala; Li Zhang; Nikhil Munshi; Donna Neuberg; Robert J Soiffer; Jerome Ritz; Edwin P Alyea; Vladimir Brusic; Kenneth C Anderson; Catherine J Wu
Journal:  Blood       Date:  2012-01-20       Impact factor: 22.113

2.  Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Authors:  R Oostvogels; E Kneppers; M C Minnema; R C Doorn; L E Franssen; T Aarts; M E Emmelot; E Spierings; I Slaper-Cortenbach; K Westinga; E Goulmy; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2016-11-14       Impact factor: 5.483

Review 3.  Bone marrow transplantation using unrelated donors for haematological malignancies.

Authors:  O Ringdén
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

Review 4.  Current drug therapy for multiple myeloma.

Authors:  Y W Huang; A Hamilton; O J Arnuk; P Chaftari; R Chemaly
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

5.  CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.

Authors:  J L Schultze; S Michalak; M J Seamon; G Dranoff; K Jung; J Daley; J C Delgado; J G Gribben; L M Nadler
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 6.  Recent developments in hematopoietic stem cell transplantation for multiple myeloma.

Authors:  William I Bensinger
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

Review 7.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

Review 8.  Role of autologous and allogeneic stem cell transplantation in myeloma.

Authors:  W I Bensinger
Journal:  Leukemia       Date:  2009-01-29       Impact factor: 11.528

Review 9.  Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?

Authors:  William I Bensinger
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

Review 10.  Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.

Authors:  Qaiser Bashir; Muzaffar H Qazilbash
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.